Contamination of dietary supplements: the impact of the undeclared compounds on health, consequences of daily usage and prevention strategies
DOI:
https://doi.org/10.12775/QS.2025.38.57810Keywords
dietary supplements, contamination, doping, sibutramine, higenamine, anabolic androgenic steroids, AAS, SMARs, DMAA, health risksAbstract
Throughout recent years, dietary supplement usage significantly increased. The reason behind it is a desire to enhance physical performance due to the healthy-body trend. As the primarily unregulated market grows, so does the possibility of consumer exploitation. By releasing products intentionally or unintentionally contaminated by undeclared active compounds, producers endanger the health of many people worldwide. Components found in ergonutritional products have a broad spectrum of properties but also many adverse effects, which may occur in long-term use, including cardiovascular, neurological complications, and hormonal imbalance, among others. It is pivotal for users to be aware of the possible risks of DS consumption and crucial for governments to tighten regulations regarding manufacturing, testing, and labeling food supplements to ensure the safety of consumers.
References
1. Directive 2002/46/EC of the European Parliament and of the Council of 10 02 on the Approximation of the Laws of the Member States Relating to Food Supplements. European Parliament and of the Council; Brussels, Belgium: 2002. pp. 51–57.
2. Wierzejska R. E. Dietary supplements—for whom? The current state of knowledge about the health effects of selected supplement use. International Journal of Environmental Research and Public Health . 2021;18(17):p. 8897. doi: 10.3390/ijerph18178897.
3. Petkova-Gueorguieva E. S., Getov I. N., Ivanov K. V., et al. Regulatory requirements for food supplements in the European Union and Bulgaria. Folia Medica . 2019;61(1):41–48. doi: 10.2478/folmed-2018-0032
4. Lewis J. D., Strom B. L. Balancing safety of dietary supplements with the free market. Annals of Internal Medicine . 2002;136(8):616–618. doi: 10.7326/0003-4819-136-8-200204160-00011.
5. Mehta N., Germain M. S., Quiel L. Dietary supplements: when too much of a good thing becomes harmful. Clinical Case Reports . 2021;9(9) doi: 10.1002/ccr3.3614.
6. Kozhuharov VR, Ivanov K, Ivanova S. Dietary Supplements as Source of Unintentional Doping. Biomed Res Int. 2022 Apr 22;2022:8387271. doi: 10.1155/2022/8387271. PMID: 35496041; PMCID: PMC9054437.
7. Oketch-Rabah H. A., Roe A. L., Muldoon-Jacobs K., Giancaspro G. I. Challenges and opportunities for improving the safety assessment of botanical dietary supplements: a United States Pharmacopeia perspective. Clinical Pharmacology and Therapeutics . 2018;104(3):426–429. doi: 10.1002/cpt.1113.
8. Starr R. R. Too little, too late: ineffective regulation of dietary supplements in the United States. American Journal of Public Health . 2015;105(3):478–485. doi: 10.2105/AJPH.2014.302348
9. Health Canada Natural and Non-Prescription. Health Products Directorate (NNHPD) About natural health product regulation in Canada. https://www.Canada.ca/En/Health-Canada/Services/
10. Zion Market Research. Dietary supplements market by ingredients (botanicals, vitamins, minerals, amino acids, enzymes) for additional supplements, medicinal supplements and sports nutrition applications - global industry perspective, comprehensive analysis and forecast . March 2022, https://www.zionmarketresearch.com/report/dietary-supplements-market
11. Knapik J.J., Steelman R.A., Hoedebecke S.S., Austin K.G., Farina E.K., Lieberman H.R. Prevalence of Dietary Supplement Use by Athletes: Systematic Review and Meta-Analysis. Sports Med. 2016;46:103–123. doi: 10.1007/s40279-015-0387-7.
12. WADA. World Anti-Doping Code. 2015. Available online: https://www.wada-ama.org/sites/default/files/resources/files/ wada-2015-world-anti-doping-code.pdf (accessed on 1 December 2022).
13. Maughan, R.J.; Burke, L.M.; Dvorak, J.; Larson-Meyer, D.E. IOC Consensus Statement: Dietary Supplements and the HighPerformance Athlete. Int. J. Sport Nutr. Exerc. Metab. 2018, 28, 23
14. Martello S., Felli M., Chiarotti M. Survey of nutritional supplements for selected illegal anabolic steroids and ephedrine using LC-MS/MS and GC-MS methods, respectively. Food Additives and Contaminants . 2007;24(3):258–265. doi: 10.1080/02652030601013729.
15. Alaedini S., Amirahmadi M., Kobarfard F., Rastegar H., Nasirahmadi S., Shoeibi S. Survey of protein-based sport supplements for illegally added anabolic steroids methyltestosterone and 4-androstenedione by UPLC-MS/MS. Steroids . 2021;165, article 108758 doi: 10.1016/j.steroids.2020.108758.
16. Cohen P. A., Travis J. C., Vanhee C., Ohana D., Venhuis B. J. Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA) and higenamine. Clinical Toxicology . 2021;59(11):975–981. doi: 10.1080/15563650.2021.1894333.
17. Martínez-Sanz JM, Sospedra I, Ortiz CM, Baladía E, Gil-Izquierdo A, Ortiz-Moncada R. Intended or Unintended Doping? A Review of the Presence of Doping Substances in Dietary Supplements Used in Sports. Nutrients. 2017 Oct 4;9(10):1093. doi: 10.3390/nu9101093. PMID: 28976928; PMCID: PMC5691710.
18. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Sibutramine. 2020 Jun 5. PMID: 31643572.
19. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999 Sep;33(9):968-78. doi: 10.1345/aph.18319. PMID: 10492502.
20. Scheen AJ. Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs. 2010;10(5):321-34. doi: 10.2165/11584800-000000000-00000. PMID: 20860415.
21. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010 Sep 2;363(10):905-17. doi: 10.1056/NEJMoa1003114. PMID: 20818901.
22. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ. 2002 May 14;166(10):1307-8. PMID: 12041851; PMCID: PMC111085.
23. Chounta A, Tsiodras S, Zouridakis S, Doumas M, Giamarellou H. Sibutramine use associated with reversible hepatotoxicity. Ann Intern Med. 2005 Nov 15;143(10):763-4. doi: 10.7326/0003-4819-143-10-200511150-00030. PMID: 16287809.
24. Shah MS, Patel ZK, Bharucha R, Talati T, Benz M. Sibutramine-Induced Nonischemic Cardiomyopathy. Cureus. 2022 Jan 26;14(1):e21650. doi: 10.7759/cureus.21650. PMID: 35242455; PMCID: PMC8884463.
25. Hudzik TJ, Patel M, Brown A. β2 -Adrenoceptor agonist activity of higenamine. Drug Test Anal. 2021 Feb;13(2):261-267. doi: 10.1002/dta.2992. Epub 2021 Jan 12. PMID: 33369180; PMCID: PMC7898339.
26. Praman S, Mulvany MJ, Williams DE, Andersen RJ, Jansakul C. Crude extract and purified components isolated from the stems of Tinospora crispa exhibit positive inotropic effects on the isolated left atrium of rats. J Ethnopharmacol. 2013 Aug 26;149(1):123-32. doi: 10.1016/j.jep.2013.06.010. Epub 2013 Jun 15. PMID: 23778316.
27. Praman S, Mulvany MJ, Williams DE, Andersen RJ, Jansakul C. Hypotensive and cardio-chronotropic constituents of Tinospora crispa and mechanisms of action on the cardiovascular system in anesthetized rats. J Ethnopharmacol. 2012 Mar 6;140(1):166-78. doi: 10.1016/j.jep.2012.01.006. Epub 2012 Jan 14. PMID: 22265931.
28. Ueki T, Akaishi T, Okumura H, Morioka T, Abe K. Biphasic tracheal relaxation induced by higenamine and nantenine from Nandina domestica Thunberg. J Pharmacol Sci. 2011;115(2):254-7. doi: 10.1254/jphs.10251sc. Epub 2011 Jan 26. PMID: 21282929.
29. Tsukiyama M, Ueki T, Yasuda Y, Kikuchi H, Akaishi T, Okumura H, Abe K. Beta2-adrenoceptor-mediated tracheal relaxation induced by higenamine from Nandina domestica Thunberg. Planta Med. 2009 Oct;75(13):1393-9. doi: 10.1055/s-0029-1185743. Epub 2009 May 25. PMID: 19468973.
30. Bai G, Yang Y, Shi Q, Liu Z, Zhang Q, Zhu YY. Identification of higenamine in Radix Aconiti Lateralis Preparata as a beta2-adrenergic receptor agonist1. Acta Pharmacol Sin. 2008 Oct;29(10):1187-94. doi: 10.1111/j.1745-7254.2008.00859.x. PMID: 18817623.
31. Kato E, Kimura S, Kawabata J. Ability of higenamine and related compounds to enhance glucose uptake in L6 cells. Bioorg Med Chem. 2017 Dec 15;25(24):6412-6416. doi: 10.1016/j.bmc.2017.10.011. Epub 2017 Oct 14. PMID: 29066136.
32. Cohen PA, Travis JC, Keizers PHJ, Boyer FE, Venhuis BJ. The stimulant higenamine in weight loss and sports supplements. Clin Toxicol (Phila). 2019 Feb;57(2):125-130. doi: 10.1080/15563650.2018.1497171. Epub 2018 Sep 6. PMID: 30188222.
33. Lee SR, Schriefer JM, Gunnels TA, Harvey IC, Bloomer RJ. Acute oral intake of a higenamine-based dietary supplement increases circulating free fatty acids and energy expenditure in human subjects. Lipids Health Dis. 2013 Oct 21;12:148. doi: 10.1186/1476-511X-12-148. PMID: 24139127; PMCID: PMC4016229.
34. Feng S, Jiang J, Hu P, Zhang JY, Liu T, Zhao Q, Li BL. A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects. Acta Pharmacol Sin. 2012 Nov;33(11):1353-8. doi: 10.1038/aps.2012.114. Epub 2012 Oct 22. PMID: 23085737; PMCID: PMC4011356.
35. Jeter J, DeZee KJ, Kennedy L. A Case of Paraspinal Muscle Rhabdomyolysis in a 22-Year-Old Male After Ingesting a Supplement Containing Higenamine. Mil Med. 2015 Jul;180(7):e847-9. doi: 10.7205/MILMED-D-14-00647. PMID: 26126260.
36. Bloomer RJ, Schriefer JM, Gunnels TA. Clinical safety assessment of oral higenamine supplementation in healthy, young men. Hum Exp Toxicol. 2015 Oct;34(10):935-45. doi: 10.1177/0960327114565490. Epub 2015 Jan 14. PMID: 25591969.
37. Yun-Choi HS, Pyo MK, Park KM, Chang KC, Lee DH. Anti-thrombotic effects of higenamine. Planta Med. 2001 Oct;67(7):619-22. doi: 10.1055/s-2001-17361. PMID: 11582538.
38. Zhang N, Lian Z, Peng X, Li Z, Zhu H. Applications of Higenamine in pharmacology and medicine. J Ethnopharmacol. 2017 Jan 20;196:242-252. doi: 10.1016/j.jep.2016.12.033. Epub 2016 Dec 19. PMID: 28007527.
39. Baume N, Mahler N, Kamber M, Mangin P, Saugy M. Research of stimulants and anabolic steroids in dietary supplements. Scand J Med Sci Sports. 2006 Feb;16(1):41-8. doi: 10.1111/j.1600-0838.2005.00442.x. PMID: 16430680.
40. Karila T, Hovatta O, Seppälä T. Concomitant abuse of anabolic androgenic steroids and human chorionic gonadotrophin impairs spermatogenesis in power athletes. Int J Sports Med. 2004 May;25(4):257-63. doi: 10.1055/s-2004-819936. PMID: 15162244.
41. Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Mar;14(1):55-69. doi: 10.1053/beem.2000.0053. PMID: 10932810.
42. Torrisi M, Pennisi G, Russo I, Amico F, Esposito M, Liberto A, Cocimano G, Salerno M, Li Rosi G, Di Nunno N, Montana A. Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review. Medicina (Kaunas). 2020 Nov 4;56(11):587. doi: 10.3390/medicina56110587. PMID: 33158202; PMCID: PMC7694262.
43. Solimini R, Rotolo MC, Mastrobattista L, Mortali C, Minutillo A, Pichini S, Pacifici R, Palmi I. Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping. Eur Rev Med Pharmacol Sci. 2017 Mar;21(1 Suppl):7-16. PMID: 28379599.
44. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs. 1983 Jun;25(6):610-20. doi: 10.2165/00003495-198325060-00004. PMID: 6347619.
45. Bertozzi G, Sessa F, Albano GD, Sani G, Maglietta F, Roshan MHK, Volti GL, Bernardini R, Avola R, Pomara C, Salerno M. The Role of Anabolic Androgenic Steroids in Disruption of the Physiological Function in Discrete Areas of the Central Nervous System. Mol Neurobiol. 2018 Jul;55(7):5548-5556. doi: 10.1007/s12035-017-0774-1. Epub 2017 Oct 2. PMID: 28971285; PMCID: PMC5994209.
46. Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev. 2019 Jan;7(1):84-94. doi: 10.1016/j.sxmr.2018.09.006. Epub 2018 Nov 30. PMID: 30503797; PMCID: PMC6326857.
47. Efimenko IV, Valancy D, Dubin JM, Ramasamy R. Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey. Int J Impot Res. 2022 Dec;34(8):757-761. doi: 10.1038/s41443-021-00465-0. Epub 2021 Sep 1. PMID: 34471228.
48. Commissioner, O. "Of the FDA in brief: FDA warns against using SARMs in body-building products." (2019).
49. Leaney AE, Beck P, Biddle S, Brown P, Grace PB, Hudson SC, Mawson DH. Analysis of supplements available to UK consumers purporting to contain selective androgen receptor modulators. Drug Test Anal. 2021 Jan;13(1):122-127. doi: 10.1002/dta.2908. Epub 2020 Aug 16. PMID: 32748554.
50. Monakhova YB, Ilse M, Hengen J, El-Atma O, Kuballa T, Kohl-Himmelseher M, Lachenmeier DW. Rapid assessment of the illegal presence of 1,3-dimethylamylamine (DMAA) in sports nutrition and dietary supplements using 1H NMR spectroscopy. Drug Test Anal. 2014 Sep;6(9):944-8. doi: 10.1002/dta.1677. Epub 2014 Jun 9. PMID: 24913715.
51. Small C, Cheng MH, Belay SS, Bulloch SL, Zimmerman B, Sorkin A, Block ER. The Alkylamine Stimulant 1,3-Dimethylamylamine Exhibits Substrate-Like Regulation of Dopamine Transporter Function and Localization. J Pharmacol Exp Ther. 2023 Aug;386(2):266-273. doi: 10.1124/jpet.122.001573. Epub 2023 Jun 22. PMID: 37348963; PMCID: PMC10353075.
52. Zhang Y, Woods RM, Breitbach ZS, Armstrong DW. 1,3-Dimethylamylamine (DMAA) in supplements and geranium products: natural or synthetic? Drug Test Anal. 2012 Dec;4(12):986-90. doi: 10.1002/dta.1368. Epub 2012 Jul 12. PMID: 22786761.
53. Karnatovskaia LV, Leoni JC, Freeman ML. Cardiac arrest in a 21-year-old man after ingestion of 1,3-DMAA-containing workout supplement. Clin J Sport Med. 2015 Jan;25(1):e23-5. doi: 10.1097/JSM.0000000000000103. PMID: 24878759.
54. Bloomer RJ, Harvey IC, Farney TM, Bell ZW, Canale RE. Effects of 1,3-dimethylamylamine and caffeine alone or in combination on heart rate and blood pressure in healthy men and women. Phys Sportsmed. 2011 Sep;39(3):111-20. doi: 10.3810/psm.2011.09.1927. PMID: 22030947.
55. Forrester M. Exposures to 1,3-dimethylamylamine-containing products reported to Texas poison centers. Hum Exp Toxicol. 2013 Jan;32(1):18-23. doi: 10.1177/0960327112454895. Epub 2012 Oct 11. PMID: 23060409.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sabina Przygodzka, Maciej Rutkiewicz, Katarzyna Gadżała, Karolina Garbino, Katarzyna Brudniak, Antoni Szuścik Szuścik, Magdalena Czyczerska

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 21
Number of citations: 0